Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2026.
-
Figures corrected NBB
Corrected annual account filed for 2023.
Financials
Financial year 2026
CORIS BIOCONCEPT from Gembloux, company number BE0459020430, closed financial year 2026 with a result of € -391,631 after tax. For that financial year CORIS BIOCONCEPT recorded revenue of € 5.5 million and equity of € 5 million. Compared with financial year 2024, the result moved from € -471,288 to € -391,631. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 14, 2026.
€ 5 million
▼ 8% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -391,631
▲ 17 % less loss than in 2024
Profit after tax over the fiscal year.
€ 815,481
▼ 49% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 4.8 million.
People and assets in 2026
31.2
▼ 0.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 2.9 million
▲ 36% vs 2024
€ 92,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 406,004
▼ 15% vs 2024
Of which on lease € 345,724.
Debts at end 2026
€ 437,835
▼ 31% vs 2024
€ 152,845 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 207,699
▼ 62% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 426,077
▲ 46% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2026 | Change 2024 → 2026 | |
|---|---|---|---|---|---|
| Revenue | - | € 5,977,824 | € 5,223,181 | € 5,452,741 | ▲ 4% |
| Gross margin | € 2,821,606 | € 1,829,671 | € 2,441,626 | € 3,064,055 | ▲ 25% |
| Profit after taxes | € -27,181 | € -852,803 | € -471,288 | € -391,631 | ▲ € 79,657 |
| Equity | € 6,963,027 | € 5,916,715 | € 5,427,346 | € 5,018,570 | ▼ 8% |
| Total debts | € 1,724,878 | € 1,701,106 | € 1,474,586 | € 1,091,348 | ▼ 26% |
| Cash | € 3,711,488 | € 2,733,982 | € 1,614,605 | € 815,481 | ▼ 49% |
| Retained profit | € 6,475,816 | € 5,623,012 | € 5,151,725 | € 4,760,094 | ▼ 8% |
| Bank debt | € 755,655 | € 884,927 | € 634,818 | € 437,835 | ▼ 31% |
| Balance sheet total | € 8,687,905 | € 7,617,821 | € 6,901,932 | € 6,109,918 | ▼ 11% |
| Employees (FTE) | 29.8 | 26.6 | 31.5 | 31.2 | ▼ 0.3 |
Key figures of CORIS BIOCONCEPT, fiscal years 2022 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.
What happened to CORIS BIOCONCEPT?
What happened at CORIS BIOCONCEPT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: loss of € 391,631. Source: NBB ↗
- Harminder SINGH became a director. NBB
- Dubey DHIRENDRA became a director. NBB
- Thierry LECLIPTEUX became a director. NBB
- New establishment in Gembloux. KBO
- New establishment in Gembloux. KBO
- Start of the company according to the CBE. KBO
In short
From € 27,181 loss in 2022 to € 391,631 loss in 2026.
Paid € 3,254 in corporate taxes since 2022.
On average € 98,200 of value added per employee in 2026.
Management
The stake of Coris Holdings comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
CORIS BIOCONCEPTBehind CORIS BIOCONCEPT are Harminder SINGH, Thierry LECLIPTEUX and Dubey DHIRENDRA. The shares are held by Coris Holdings (100%).
Directors
According to the 2026 annual accounts
since 2025
since 2023
since 2025
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Guillaume Fouquet,Isnes 11
5032 Gembloux
Rue Jean Sonet,Isnes 4 box A
5032 Gembloux
Active since 30 October 1996
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0459.020.430
- VAT number
- BE 0459.020.430
- Registered office
- Rue Guillaume Fouquet,Isnes 11, 5032 Gembloux
- Names & denominations
- CORIS BIOCONCEPT
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 16 October 1996
- Peppol
- Active · Active since 1 Dec 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Activiteiten op het gebied van voeding
Overige activiteiten i.v.m. gezondheidszorg, n.e.g.
Overige menselijke gezondheidszorg, n.e.g.
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels